Account
Inquiry
Tirzepatide 10mg is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist currently under investigation for type 2 diabetes treatment and weight management applications. Our tirzepatide 10mg is supplied in high purity (99.9%) pharmaceutical grade formulation, packaged in sterile vials for research use.
Clinical studies have demonstrated that tirzepatide 10mg shows superior efficacy in glucose control and weight reduction compared to selective GLP-1 receptor agonists. The compound's unique mechanism combines the beneficial effects of both GIP and GLP-1 pathways in a single molecule.
In clinical trials, subjects receiving tirzepatide 10mg weekly doses achieved significant weight reduction results. The SURMOUNT-1 trial reported an average 19.5% weight loss after 72 weeks with the 10mg dosage. This makes tirzepatide 10mg a promising candidate for obesity-related research.
The molecular structure of tirzepatide features a PEG-modified lysine side chain that enhances water solubility while maintaining biological activity. This modification contributes to the compound's extended half-life, allowing for once-weekly administration in clinical settings.
Our tirzepatide 10mg is strictly for research purposes and is not intended for human consumption. Researchers should follow proper peptide storage protocols, including protection from light, moisture, and repeated freeze-thaw cycles to maintain stability.
As a manufacturer, we offer flexible ordering options including wholesale quantities and custom synthesis services. All batches undergo rigorous quality control testing to ensure consistent purity and performance in research applications.
